Iovance Biotherapeutics - IOVA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $24.00
  • Forecasted Upside: 93.86 %
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$12.38
▼ -0.41 (-3.21%)

This chart shows the closing price for IOVA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Iovance Biotherapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IOVA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IOVA

Analyst Price Target is $24.00
▲ +93.86% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Iovance Biotherapeutics in the last 3 months. The average price target is $24.00, with a high forecast of $43.00 and a low forecast of $13.00. The average price target represents a 93.86% upside from the last price of $12.38.

This chart shows the closing price for IOVA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 10 investment analysts is to buy stock in Iovance Biotherapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/24/2021
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/25/2021
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/23/2021
  • 0 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/21/2021
  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/19/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/20/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/19/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/18/2022

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/18/2022Wells Fargo & CompanyReiterated RatingEqual Weight$14.00Low
8/5/2022Chardan CapitalLower Target$31.00 ➝ $30.00Low
8/5/2022Robert W. BairdLower TargetOutperform$34.00 ➝ $25.00Low
7/1/2022The Goldman Sachs GroupLower TargetBuy$64.00 ➝ $18.00Low
6/8/2022JMP SecuritiesReiterated RatingBuy$25.00Low
5/27/2022Truist FinancialLower Target$20.00High
5/27/2022OppenheimerLower TargetOutperform$31.00 ➝ $27.00High
5/27/2022Chardan CapitalLower TargetBuy$44.00 ➝ $31.00High
5/27/2022Piper SandlerLower TargetNeutral$20.00 ➝ $13.00High
5/24/2022The Goldman Sachs GroupLower TargetBuy$79.00 ➝ $64.00Low
4/7/2022Truist FinancialLower Target$32.00 ➝ $29.00High
4/7/2022Robert W. BairdBoost TargetOutperform$30.00 ➝ $34.00High
2/28/2022Truist FinancialLower Target$45.00 ➝ $32.00Medium
2/25/2022Chardan CapitalLower TargetBuy$50.00 ➝ $45.00High
2/25/2022Robert W. BairdLower TargetOutperform$35.00 ➝ $30.00High
1/28/2022Stifel NicolausUpgradeHold ➝ Buy$23.00 ➝ $25.00High
1/5/2022Wells Fargo & CompanyLower Target$35.00 ➝ $25.00High
12/7/2021CowenInitiated CoverageOutperformMedium
11/15/2021OppenheimerLower TargetOutperform$38.00 ➝ $31.00Low
11/5/2021HC WainwrightLower TargetBuy$46.00 ➝ $43.00High
11/5/2021Piper SandlerBoost TargetNeutral$18.00 ➝ $20.00High
8/24/2021Robert W. BairdReiterated RatingBuy$35.00Medium
8/11/2021JMP SecuritiesReiterated RatingBuyLow
7/7/2021Chardan CapitalReiterated RatingBuyHigh
6/29/2021MizuhoInitiated CoverageBuy$30.00High
6/29/2021Chardan CapitalReiterated RatingBuy$51.00High
6/10/2021JMP SecuritiesUpgradeMarket Perform ➝ Outperform$32.00High
5/26/2021Piper SandlerReiterated RatingOverweight ➝ Neutral$35.00 ➝ $18.00Low
5/25/2021OppenheimerLower TargetOutperform$51.00 ➝ $38.00N/A
5/20/2021Robert W. BairdLower TargetOutperform$55.00 ➝ $35.00High
5/20/2021MizuhoBoost TargetBuy$30.00 ➝ $55.00High
5/20/2021Piper SandlerDowngradeOverweight ➝ Neutral$35.00 ➝ $18.00High
5/19/2021Stifel NicolausDowngradeBuy ➝ HoldHigh
5/19/2021Chardan CapitalLower TargetBuy$54.00 ➝ $51.00High
5/19/2021OppenheimerLower TargetOutperform$57.00 ➝ $51.00High
5/19/2021JMP SecuritiesLower TargetOutperform ➝ Market Perform$45.00 ➝ $43.00High
5/19/2021BarclaysLower TargetOverweight$60.00 ➝ $40.00High
5/19/2021HC WainwrightLower TargetBuy$50.00 ➝ $46.00High
5/19/2021Piper SandlerLower TargetOverweight$45.00 ➝ $35.00High
5/3/2021Truist FinancialInitiated CoverageBuy$50.00Low
4/16/2021The Goldman Sachs GroupInitiated CoverageBuyHigh
3/8/2021HC WainwrightUpgradeNeutral ➝ Buy$50.00High
3/1/2021Chardan CapitalReiterated RatingBuyHigh
1/14/2021OppenheimerBoost TargetOutperform$43.00 ➝ $57.00Medium
12/17/2020BarclaysBoost TargetPositive ➝ Overweight$43.00 ➝ $55.00Low
12/15/2020HC WainwrightDowngradeBuy ➝ NeutralHigh
11/9/2020JMP SecuritiesBoost TargetMarket Outperform$38.00 ➝ $45.00Low
11/6/2020BarclaysBoost TargetOverweight$36.00 ➝ $43.00Medium
11/6/2020Piper SandlerBoost TargetOverweight$35.00 ➝ $45.00Medium
10/15/2020Wells Fargo & CompanyBoost TargetEqual Weight ➝ Equal Weight$29.00 ➝ $35.00High
10/6/2020Stifel NicolausLower Target$47.00 ➝ $42.00High
10/6/2020BarclaysLower TargetOverweight$45.00 ➝ $36.00High
10/6/2020HC WainwrightLower TargetBuy$48.00 ➝ $46.00High
10/6/2020Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$49.00 ➝ $29.00High
10/6/2020OppenheimerReiterated RatingBuy$43.00High
10/6/2020Chardan CapitalReiterated RatingBuy$53.00 ➝ $50.00High
8/7/2020Chardan CapitalBoost TargetBuy$44.00 ➝ $53.00High
8/7/2020OppenheimerReiterated RatingBuy$43.00High
6/15/2020OppenheimerInitiated CoverageBuy$43.00Low
5/28/2020Stifel NicolausBoost TargetBuy$48.00 ➝ $50.00High
5/27/2020Chardan CapitalReiterated RatingBuyHigh
5/14/2020Chardan CapitalReiterated RatingBuy$44.00Medium
5/6/2020Robert W. BairdBoost TargetOutperform$60.00 ➝ $65.00Medium
5/5/2020OppenheimerInitiated CoverageBuy$43.00Low
5/5/2020MizuhoReiterated RatingBuy$61.00Low
4/29/2020HC WainwrightBoost TargetPositive ➝ Buy$36.00 ➝ $48.00High
4/28/2020OppenheimerInitiated CoverageBuy$35.00 ➝ $43.00High
4/27/2020Chardan CapitalBoost TargetBuy$36.00 ➝ $44.00High
4/27/2020MizuhoReiterated RatingBuy$61.00Low
4/21/2020MizuhoInitiated CoverageBuyLow
3/4/2020BarclaysInitiated CoverageOverweight$45.00Medium
2/26/2020Piper SandlerBoost TargetOutperform$40.00Medium
2/26/2020Chardan CapitalReiterated RatingBuy$36.00Medium
2/26/2020OppenheimerReiterated RatingOutperform$32.00 ➝ $35.00High
2/26/2020CowenReiterated RatingBuyHigh
2/26/2020HC WainwrightBoost TargetBuy$32.00 ➝ $36.00High
2/26/2020Wells Fargo & CompanyBoost TargetOverweight$32.00 ➝ $38.00High
1/13/2020CowenInitiated CoverageBuyHigh
12/18/2019JMP SecuritiesInitiated CoverageOutperform$38.00Medium
11/21/2019HC WainwrightReiterated RatingBuy$32.00High
11/21/2019Chardan CapitalReiterated RatingBuy$33.00High
11/8/2019Chardan CapitalReiterated RatingBuy$33.00High
11/5/2019HC WainwrightReiterated RatingBuy$32.00High
9/30/2019Stifel NicolausInitiated CoverageBuy$27.00Low
8/26/2019Jefferies Financial GroupSet TargetBuy$33.00Low
8/16/2019B. RileySet TargetBuy$28.00Medium
7/3/2019OppenheimerSet TargetBuy$32.00Low
7/2/2019HC WainwrightReiterated RatingBuy$32.00Medium
6/28/2019Piper Jaffray CompaniesBoost TargetOverweight$20.00 ➝ $30.00High
6/3/2019Jefferies Financial GroupBoost TargetBuy$29.00 ➝ $33.00High
6/3/2019UBS GroupBoost TargetOutperform$25.00 ➝ $30.00Medium
6/3/2019HC WainwrightBoost TargetBuy$26.00 ➝ $32.00High
5/31/2019Chardan CapitalReiterated RatingBuy$30.00High
5/23/2019HC WainwrightReiterated RatingBuy$26.00Low
5/23/2019Wells Fargo & CompanyBoost TargetOutperform$23.00 ➝ $32.00Low
5/20/2019Chardan CapitalSet TargetBuy$30.00Medium
5/17/2019B. RileySet TargetBuy$24.00Medium
5/16/2019Robert W. BairdBoost TargetOutperform$29.00 ➝ $34.00Medium
4/29/2019Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$20.00High
4/23/2019Chardan CapitalReiterated RatingBuyHigh
4/5/2019B. RileyReiterated RatingBuyLow
4/2/2019Chardan CapitalReiterated RatingBuy$20.00High
4/1/2019HC WainwrightReiterated RatingBuy$26.00Low
3/19/2019OppenheimerReiterated RatingBuyLow
3/13/2019Chardan CapitalReiterated RatingBuyMedium
2/28/2019Chardan CapitalReiterated RatingBuy ➝ Buy$30.00 ➝ $20.00High
2/6/2019Robert W. BairdInitiated CoverageOutperform ➝ Outperform$29.00 ➝ $29.00High
1/11/2019OppenheimerSet TargetBuy$25.00Low
12/31/2018B. RileyInitiated CoverageBuy ➝ Buy$24.00 ➝ $24.00Medium
11/12/2018HC WainwrightReiterated RatingBuy$26.00High
11/6/2018CowenReiterated RatingBuyHigh
10/12/2018HC WainwrightReiterated RatingBuy$22.00 ➝ $26.00High
10/12/2018CitigroupBoost TargetPositive ➝ Outperform$22.00 ➝ $25.00High
9/25/2018HC WainwrightReiterated RatingBuy$22.00High
9/6/2018HC WainwrightSet TargetBuy$22.00High
8/7/2018HC WainwrightSet TargetBuy$22.00High
7/6/2018Chardan CapitalReiterated RatingBuy$30.00High
6/13/2018HC WainwrightSet TargetBuy$22.00High
5/11/2018B. RileyBoost TargetBuy ➝ Buy$22.00 ➝ $24.00Low
5/11/2018HC WainwrightReiterated RatingBuy$22.00High
4/10/2018B. RileyUpgradeNeutral ➝ Buy$22.00Low
3/13/2018HC WainwrightSet TargetBuy$22.00High
3/13/2018B. RileyBoost TargetNeutral ➝ Neutral$18.50 ➝ $22.00High
2/23/2018B. RileyReiterated RatingBuy ➝ Neutral$18.00 ➝ $18.50High
2/9/2018Jefferies Financial GroupBoost TargetBuy$31.00Low
2/8/2018HC WainwrightSet TargetBuy$22.00High
1/31/2018OppenheimerBoost TargetOutperform ➝ Outperform$13.00 ➝ $19.00Low
1/29/2018Wells Fargo & CompanyReiterated RatingBuy$23.00Medium
1/25/2018B. RileyReiterated RatingBuy$18.00Medium
1/25/2018HC WainwrightBoost TargetBuy ➝ Buy$16.00 ➝ $22.00High
1/22/2018Chardan CapitalReiterated RatingBuyHigh
1/17/2018HC WainwrightSet TargetBuy$16.00High
12/14/2017HC WainwrightSet TargetBuy$16.00High
12/14/2017OppenheimerSet TargetBuy$13.00High
12/13/2017B. RileyReiterated RatingBuy$18.00Low
11/13/2017HC WainwrightReiterated RatingBuy$16.00N/A
11/13/2017B. RileyReiterated RatingBuy$18.00N/A
11/13/2017OppenheimerReiterated RatingBuy$13.00N/A
11/1/2017B. RileyBoost TargetBuy$17.50 ➝ $18.00N/A
10/31/2017OppenheimerSet TargetBuy$13.00N/A
10/30/2017HC WainwrightSet TargetBuy$16.00N/A
10/29/2017Jefferies Financial GroupReiterated RatingBuyN/A
10/25/2017FBR & Co.Reiterated RatingBuy$17.50N/A
10/12/2017OppenheimerSet TargetBuy$13.00N/A
9/26/2017OppenheimerReiterated RatingBuy$13.00Low
9/13/2017HC WainwrightReiterated RatingBuy$16.00High
9/11/2017OppenheimerSet TargetBuy$13.00Low
9/7/2017Chardan CapitalReiterated RatingBuyHigh
9/5/2017Jefferies Financial GroupReiterated RatingBuy$11.00High
9/1/2017Chardan CapitalReiterated RatingBuy$20.00High
8/31/2017HC WainwrightReiterated RatingBuy$16.00Medium
8/18/2017OppenheimerSet TargetBuy$13.00Low
(Data available from 8/18/2017 forward)

News Sentiment Rating

0.25 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
1/20/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/19/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
3/21/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/20/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
5/20/2022
  • 3 very positive mentions
  • 7 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
6/19/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/19/2022
  • 1 very positive mentions
  • 8 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
8/18/2022

Current Sentiment

  • 1 very positive mentions
  • 8 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Iovance Biotherapeutics logo
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Read More

Today's Range

Now: $12.38
Low: $11.96
High: $12.63

50 Day Range

MA: $11.27
Low: $7.68
High: $13.05

52 Week Range

Now: $12.38
Low: $6.18
High: $27.96

Volume

142,876 shs

Average Volume

2,468,660 shs

Market Capitalization

$1.95 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.47

Frequently Asked Questions

What sell-side analysts currently cover shares of Iovance Biotherapeutics?

The following Wall Street research analysts have issued reports on Iovance Biotherapeutics in the last twelve months: Chardan Capital, Cowen Inc, HC Wainwright, JMP Securities, Oppenheimer Holdings Inc., Piper Sandler, Robert W. Baird, Stifel Nicolaus, StockNews.com, The Goldman Sachs Group, Inc., Truist Financial Co., and Wells Fargo & Company.
View the latest analyst ratings for IOVA.

What is the current price target for Iovance Biotherapeutics?

10 Wall Street analysts have set twelve-month price targets for Iovance Biotherapeutics in the last year. Their average twelve-month price target is $24.00, suggesting a possible upside of 93.9%. HC Wainwright has the highest price target set, predicting IOVA will reach $43.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $13.00 for Iovance Biotherapeutics in the next year.
View the latest price targets for IOVA.

What is the current consensus analyst rating for Iovance Biotherapeutics?

Iovance Biotherapeutics currently has 2 hold ratings and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IOVA will outperform the market and that investors should add to their positions of Iovance Biotherapeutics.
View the latest ratings for IOVA.

What other companies compete with Iovance Biotherapeutics?

How do I contact Iovance Biotherapeutics' investor relations team?

Iovance Biotherapeutics' physical mailing address is 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070. The biotechnology company's listed phone number is (650) 260-7120 and its investor relations email address is [email protected] The official website for Iovance Biotherapeutics is www.iovance.com. Learn More about contacing Iovance Biotherapeutics investor relations.